The outcomes of Checkmate 142 in mCRC

The outcomes of Checkmate 142 in mCRC

obr

1 year
81 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
John Leighton, MD, shares the outcomes of the Checkmate 142 study examining ipilimumab and nivolumab in metastatic colorectal cancer (mCRC) patients at Annual Meeting 2018.
Up Next Autoplay